Table 2.
Number of patients who ever received a drug from onset to last available follow-up visit, with the corresponding days of drug exposure per medication from the first day of drug administration to the last available follow-up visit
| Pharmachild N = 8274 Days of drug exposure |
BiKeR N = 3990 Days of drug exposure |
Sweden N = 3020 Days of drug exposure |
||
|---|---|---|---|---|
| DMARDs | Methotrexate | 6963 (84.2%); 924 (449–1747) |
3344 (83.8%); 494 (173–957) |
1842 (61%); 1198 (555–2127) |
| Sulfasalazine | 861 (10.4%); 360 (143–730) |
274 (6.9%); 174 (32–470) |
95 (3%) 443 (132–1042) |
|
| Cyclosporine | 518 (6.3%); 616 (235–1358) |
113 (2.8%); 186 (62–580) |
16 (0.5%); 584 (250–1452) |
|
| Leflunomide | 372 (4.5%); 434 (182–888) |
219 (5.5%); 267 (68–701) |
2 (0.1%); 840 (511–1169) |
|
| Hydroxychloroquine | 279 (3.4%); 486 (202–1022) |
106 (2.7%); 182 (1–535) |
32 (1.1%); 957 (311–1612) |
|
| Azathioprine | 108 (1.3%); 439 (187–973) |
155 (3.9%); 186 (26–494) |
31 (1%); 1171 (340–2179) |
|
| Thalidomide | 35 (0.4%); 290 (85–665) |
0 | 0 | |
| Systemic glucocorticoids | 3299 (39.9%) 206 (67–648) |
1680 (42.1%) 196 (81–449) |
503 (16.7%) 91 (35–437) |
|
| Biologics | Etanercept | 3600 (43.5%); 719 (300–1338) |
2467 (61.8%); 489 (184–934) |
726 (24%); 827 (341–1666) |
| Adalimumab | 1778 (21.5%); 442 (174–927) |
810 (20.3%); 350 (117–755) |
657 (21.8%); 701 (292–1604) |
|
| Infliximab | 705 (8.5%); 425 (160–951) |
68 (1.7%); 213 (129–717) |
189 (6.3%); 825 (328–1738) |
|
| Tocilizumab | 633 (7.7%); 351 (126–742) |
281 (7%); 377 (127–730) |
122 (4%); 660 (193–1353) |
|
| Abatacept | 420 (5.1%); 342 (156–715) |
101 (2.5%); 190 (83–582) |
80 (2.6%); 378 (164–1125 |
|
| Anakinra | 339 (4.1%); 299 (94–837) |
50 (1.3%); 304 (9–806) |
48 (1.6%); 422 (144–836) |
|
| Golimumab | 161 (1.9%); 270 (106–623) |
63 (1.6%); 344 (88–783) |
93 (3.1%); 796 (370–1743) |
|
| Canakinumab | 145 (1.8%); 351 (133–1032) |
39 (1%); 364 (214–733) |
7 (0.2%); 654 (604–1654) |
|
| Rituximab | 103 (1.2%); 42 (24–87) |
4 (0.1%); 15 (0–108) |
20 (0.7%); 129 (15–1550) |
|
| Certolizumab | 33 (0.4%); 166 (106–309) |
4 (0.1%); 49 (0–110) |
8 (0.3%); 984 (714–1538) |
|
| Other biologic agents | 14 (0.2%); 217 (54–432) |
4 (0.1%); 77 (25–149) |
2 (0.1%); 325 (223–426) |
Data are numbers of patients with frequencies (percentage), and medians and 1st–3rd quartiles of days of drug exposure
Abbreviations: BiKeR Biologics in Pediatric Rheumatology Registry, DMARD disease-modifying anti-rheumatic drug